MSI Testing’s Impact on Immunotherapy in Gastric Cancers – OncLive
OncLive |
MSI Testing's Impact on Immunotherapy in Gastric Cancers
OncLive And our data from MSKCC in the metastatic setting, which was recently published in Cancer Discovery, shows that MSI metastatic gastric cancer progresses on systemic chemotherapy within the first 4 months of treatment, showing that these tumors are … |
